Search over 3,000 reports

    Tezacaftor (VX-661) + Ivacaftor - Launch Insight, 2017

    Tezacaftor (VX-661) + Ivacaftor - Launch Insight, 2017
    Date: Jan, 2018
    Type: Pharmaceutical Industry Report
    Pages: 50
    Geography: Global
    Delivery Timeline: 48 hours
    SKU: DILI0012
    "Tezacaftor (VX-661) + Ivacaftor - Launch Insight, 2018" report by DelveInsight provides comprehensive insights about Tezacaftor (VX-661) + Ivacaftor 's launch. The report covers all indications for which Tezacaftor (VX-661) + Ivacaftor is being developed and also provides its competitive landscape for the major indications. The report further includes patent details, forecasted sales till 2022 and post launch market positioning.

    Tezacaftor (VX-661) + Ivacaftor Post-Launch Market Positioning Scenario
    The report will provide a clear picture of market positioning of the upcoming launch of Tezacaftor (VX-661) + Ivacaftor and will also provide the insight about how Tezacaftor (VX-661) + Ivacaftor will evolve in the market as well as within its respective class. Report provides detailed information of clinical trials that have been or are being conducted for this product. Analysis and Insightful information around the clinical trials is provided by assessment of the trial results.

    Tezacaftor (VX-661) + Ivacaftor Attributes Analysis
    Attributes analysis carried out by our analysts helps in understanding how the upcoming launch scores itself in comparison to other competitors (both marketed and pipeline). The scoring and analysis has been based upon scrutinizing data from all key clinical trials for the product. A head to head comparison with marketed products if available is scanned thoroughly. Further, analyzing data of other competitors with regards to the product also assists in proper scoring of the product in its space.

    Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
    Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

    Scope of the report
    • Detailed product description including its chemical properties, molecule type and mechanism of action
    • Detailed description of non-clinical and clinical studies for all the indications
    • Patent expiry analysis of the drug along with other competitors in the market
    • Forecasted sales till 2022
    • Tezacaftor (VX-661) + Ivacaftor market positioning analysis
    • Tezacaftor (VX-661) + Ivacaftor class share evolution

    Reasons to Buy
    • Establish a comprehensive understanding of the emerging product, Tezacaftor (VX-661) + Ivacaftor
    • Understand Tezacaftor (VX-661) + Ivacaftor `s therapeutic performance through pre-clinical and clinical characterization in its associated indications
    • Identify the upcoming launch timeline of Tezacaftor (VX-661) + Ivacaftor
    • Plan effective competitive strategy by understanding Tezacaftor (VX-661) + Ivacaftor `s market positioning post-launch and its in-class market evolution
    • Plan counter-effective strategies around Tezacaftor (VX-661) + Ivacaftor `s patents expiry details
    • Understand and analyze post launch growth prospects of Tezacaftor (VX-661) + Ivacaftor through its forecasted sales
    • Identify Tezacaftor (VX-661) + Ivacaftor `s attributes and use it for target finding, drug repurposing, and precision medicine
    • Identify the competitors in the same space as Tezacaftor (VX-661) + Ivacaftor
    1. Report Introduction
    2. Tezacaftor (VX-661) + Ivacaftor Overview
    3. Tezacaftor (VX-661) + Ivacaftor : Mechanism of action
    4. Pre-clinical Characterization
    • Indication 1
    • Indication 2
    5. Clinical Characterization
    • Indication 1
    • Indication 2
    6. Product Developmental Activities
    • Collaboration
    • Mergers & Acquisitions
    • Financing
    7. Tezacaftor (VX-661) + Ivacaftor Market Evolution
    8. Tezacaftor (VX-661) + Ivacaftor Class Share Evolution
    9. Tezacaftor (VX-661) + Ivacaftor Market Positioning
    10. Patent Expiry Analysis
    11. Competitive Landscape for Tezacaftor (VX-661) + Ivacaftor in major indications
    Consulting Services
    About DelveInsight
    Contact Us
    Note: Certain sections of the table of contents would vary according to the availability of information
    Table 1: Tezacaftor (VX-661) + Ivacaftor , Heat Map
    Table 2: Clinical Trial Landscape
    Table 3: Clinical Efficacy Data from Cross Trials
    Table 4: Competitive Landscape for Tezacaftor (VX-661) + Ivacaftor in Indication 1
    Table 5: Competitive Landscape for Tezacaftor (VX-661) + Ivacaftor in Indication 2
    Figure 1: Tezacaftor (VX-661) + Ivacaftor Developmental Milestones
    Figure 2: Tezacaftor (VX-661) + Ivacaftor Sales Forecast till 2022
    Figure 3: Tezacaftor (VX-661) + Ivacaftor Class Share Evolution
    Figure 4: Comparative Analysis of Tezacaftor (VX-661) + Ivacaftor with Marketed Products in the same class
    Figure 5: Patent Expiry Analysis
    Tezacaftor (VX-661) + Ivacaftor

    Vertex Pharmaceuticals

    Cystic Fibrosis (CF)
    • Single User License
      (20% Off)
    • Site License
      (30% Off)
    • Global License
      (40% Off)

    Contact Us

    +91-11-45689769, +91 9650213330


    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap